Search Results

Displaying Results 226-250 of 294 "'INT'"
Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.

Sep 29, 2025, 02:38 ET Leqembi® approved for IV maintenance treatment in China

[iv] Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706. This information was brought to you by

More news about: BioArctic

Sep 29, 2025, 02:34 ET Leqembi® approved for IV maintenance treatment in China

[iv] Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706. This information was brought to you by

More news about: BioArctic

Zimmer Biomet Announces Japan PMDA Approval of World's First Iodine-Treated Total Hip Replacement System

Sep 25, 2025, 16:30 ET Zimmer Biomet Announces Japan PMDA Approval of World's First Iodine-Treated Total Hip Replacement System

A V. Three-Year Results with a Ringless Third- Generation Porous Plasma Sprayed Acetabular Component in Primary Total Hip Arthroplasty. Surg Technol Int [Internet]. 2017 Jan; 30:295—299. Available from:

More news about: Zimmer Biomet Holdings, Inc.

The Hidden Genetic Threat Putting 1 in 5 at Cardiovascular Disease Risk: Global Experts Call for Action on Elevated Lipoprotein(a)

Sep 24, 2025, 06:26 ET The Hidden Genetic Threat Putting 1 in 5 at Cardiovascular Disease Risk: Global Experts Call for Action on Elevated Lipoprotein(a)

14;43(39):3925-3946[6] Vinci P et al. Lipoprotein(a) as a Risk Factor for Cardiovascular Diseases: Pathophysiology and Treatment Perspectives. Int J Environ Res Public Health. 2023 Sep 6;20(18):6721[7] Novartis-commissioned online survey, March 17–30, 2025;

More news about: Global Heart Hub & Novartis

隱藏的基因威脅：全球五分之一人口面臨心血管疾病風險--專家呼籲應對脂蛋白(a) 升高

Sep 24, 2025, 06:23 ET 隱藏的基因威脅：全球五分之一人口面臨心血管疾病風險--專家呼籲應對脂蛋白(a) 升高

14;43(39):3925-3946[6] Vinci P et al. Lipoprotein(a) as a Risk Factor for Cardiovascular Diseases: Pathophysiology and Treatment Perspectives. Int J Environ Res Public Health. 2023 Sep 6;20(18):6721[7] Novartis-commissioned online survey, March 17–30, 2025;

More news about: Global Heart Hub & Novartis

심혈관 질환 발생 위험을 야기하는 유전적 위험 인자: 글로벌 전문가들, Lp(a)에 대한 대응 촉구

Sep 24, 2025, 06:21 ET 심혈관 질환 발생 위험을 야기하는 유전적 위험 인자: 글로벌 전문가들, Lp(a)에 대한 대응 촉구

14;43(39):3925-3946[6] Vinci P et al. Lipoprotein(a) as a Risk Factor for Cardiovascular Diseases: Pathophysiology and Treatment Perspectives. Int J Environ Res Public Health. 2023 Sep 6;20(18):6721[7] Novartis-commissioned online survey, March 17–30, 2025;

More news about: Global Heart Hub & Novartis

BANC3 Secures Defense Contract to Develop Wideband Non-blocking RF Switch Matrix for Next-Generation Electronic Warfare

Sep 22, 2025, 09:07 ET BANC3 Secures Defense Contract to Develop Wideband Non-blocking RF Switch Matrix for Next-Generation Electronic Warfare

modernization efforts. Opportunities include integration into U.S. Navy and Air Force initiatives such as the P-8 Poseidon SIGINT upgrade, the MQ-4 Triton Multi-INT upgrade, and AFSPECWAR Tactical Air Control Party (TACP) missions. In addition, the system aligns with the Pentagon's broader Joint All-Domain Command

More news about: BANC3

Anti-MTBR (microtubule binding region) Tau Antibody Etalanetug Granted FDA Fast Track Designation

Sep 16, 2025, 19:31 ET Anti-MTBR (microtubule binding region) Tau Antibody Etalanetug Granted FDA Fast Track Designation

doi:10.1038/s41467-021-23507-zOno K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706.Hampel H, Hardy J, Blennow K, et al. The amyloid

More news about: Eisai Inc.

Johnson & Johnson to showcase industry-leading neuropsychiatry innovations at the 2025 Psych Congress Annual Meeting

Sep 15, 2025, 08:00 ET Johnson & Johnson to showcase industry-leading neuropsychiatry innovations at the 2025 Psych Congress Annual Meeting

on Mental Illness.Alphs L, et al. Factors associated with relapse in schizophrenia despite adherence to long-acting injectable therapy. Int Clin Psychopharmacol. 2016;31(4)202-209. doi:10.1097/YIC.0000000000000125© Johnson & Johnson 2025. All rights reserved.

More news about: Johnson & Johnson

Intensity Therapeutics Reports INVINCIBLE-4, Presurgical Triple-Negative Breast Cancer Study Update

Sep 10, 2025, 07:47 ET Intensity Therapeutics Reports INVINCIBLE-4, Presurgical Triple-Negative Breast Cancer Study Update

response, while also providing a good appearance post-surgery." About INT230-6 INT230-6, Intensity's lead proprietary investigational product candidate, is designed for direct intratumoral injection. INT230-6 was discovered using Intensity's proprietary DfuseRx℠ technology platform.

More news about: Intensity Therapeutics Inc.

AliveDx presenta el formulario 510(k) ante la Administración de Fármacos y Alimentos de Estados Unidos (FDA)

Sep 04, 2025, 11:33 ET AliveDx presenta el formulario 510(k) ante la Administración de Fármacos y Alimentos de Estados Unidos (FDA)

Classification Criteria.Ann Rheum Dis. 2022;81(3):309-314.  KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4S):S1-S276.  Logo: https://mma.prnewswire.com/media/2657402/5489172/AliveDx_Logo.jpg

More news about: AliveDx

AliveDx annonce la présentation d'une notification 510(k) à la Food and Drug Administration (FDA) américaine pour son test MosaiQ AiPlex® Vasculitis (VAS)

Sep 03, 2025, 13:04 ET AliveDx annonce la présentation d'une notification 510(k) à la Food and Drug Administration (FDA) américaine pour son test MosaiQ AiPlex® Vasculitis (VAS)

Classification Criteria.Ann Rheum Dis. 2022;81(3):309-314. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4S):S1-S276.  Logo : https://mma.prnewswire.com/media/2657402/5489172/AliveDx_Logo.jpg

More news about: AliveDx

Sep 03, 2025, 11:35 ET AliveDx gibt die Einreichung eines 510(k)-Antrags bei der US-amerikanischen Food and Drug Administration (FDA) für seinen MosaiQ AiPlex® Vasculitis (VAS)-Assay bekannt.

Classification Criteria.Ann Rheum Dis. 2022;81(3):309-314. KDIGO 2021 Klinische Praxisleitlinie für die Behandlung von Glomerularkrankheiten. Kidney Int. 2021;100(4S):S1-S276. Logo: https://mma.prnewswire.com/media/2657402/5489172/AliveDx_Logo.jpg

More news about: AliveDx

AliveDx announces U.S. Food and Drug Administration (FDA) 510(k) submission for its MosaiQ AiPlex® Vasculitis (VAS) assay.

Sep 03, 2025, 09:00 ET AliveDx announces U.S. Food and Drug Administration (FDA) 510(k) submission for its MosaiQ AiPlex® Vasculitis (VAS) assay.

Classification Criteria.Ann Rheum Dis. 2022;81(3):309-314.   KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4S):S1-S276.   Logo: https://mma.prnewswire.com/media/2657402/5489172/AliveDx_Logo.jpg

More news about: AliveDx

AliveDx announces U.S. Food and Drug Administration (FDA) 510(k) submission for its MosaiQ AiPlex® Vasculitis (VAS) assay.

Sep 03, 2025, 09:00 ET AliveDx announces U.S. Food and Drug Administration (FDA) 510(k) submission for its MosaiQ AiPlex® Vasculitis (VAS) assay.

Classification Criteria.Ann Rheum Dis. 2022;81(3):309-314.   KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4S):S1-S276.   Logo: https://mma.prnewswire.com/media/2657402/5489172/AliveDx_Logo.jpg

More news about: AliveDx

Sep 02, 2025, 23:06 ET Rolling sBLA initiated to the U.S. FDA for Leqembi® Iqlik™ (lecanemab-irmb) as a subcutaneous starting dose for the treatment of early Alzheimer's disease under Fast Track status

doi:10.1038/s41467-021-23507-z 2 Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706. 3 Hampel H, Hardy J, Blennow K, et al. The

More news about: BioArctic

Sep 02, 2025, 23:01 ET Rolling sBLA initiated to the U.S. FDA for Leqembi® Iqlik™ (lecanemab-irmb) as a subcutaneous starting dose for the treatment of early Alzheimer's disease under Fast Track status

doi:10.1038/s41467-021-23507-z 2 Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706. 3 Hampel H, Hardy J, Blennow K, et al. The

More news about: BioArctic

Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status

Sep 02, 2025, 19:30 ET Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status

doi:10.1038/s41467-021-23507-zOno K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706.Hampel H, Hardy J, Blennow K, et al. The amyloid

More news about: Eisai Inc.

FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease

Sep 02, 2025, 15:58 ET FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease

1993;43(11):2412-4.Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706.

More news about: Eisai Inc.

Intensity Therapeutics, Inc. to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 02, 2025, 07:47 ET Intensity Therapeutics, Inc. to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

https://hcwevents.com/annualconference/ About INT230-6 INT230-6, Intensity's lead proprietary investigational product candidate, is designed for direct intratumoral injection. INT230-6 was discovered using Intensity's proprietary DfuseRx℠ technology platform.

More news about: Intensity Therapeutics Inc.

Aug 29, 2025, 18:13 ET US FDA approves Leqembi® IQKLIK™ (lecanemab-irmb) subcutaneous injection for maintenance dosing for the treatment of early Alzheimer's disease

1993;43(11):2412-4.ii  Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706. This information was brought to you by Cision

More news about: BioArctic

Aug 29, 2025, 18:11 ET US FDA approves Leqembi® IQKLIK ™ (lecanemab-irmb) subcutaneous injection for maintenance dosing for the treatment of early Alzheimer's disease

1993;43(11):2412-4.ii  Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706. This information was brought to you by Cision

More news about: BioArctic

Vanda Pharmaceuticals Announces FDA Granted Orphan Drug Designation for VGT-1849B, a Novel and Selective Candidate for the Treatment of Polycythemia Vera

Aug 28, 2025, 07:00 ET Vanda Pharmaceuticals Announces FDA Granted Orphan Drug Designation for VGT-1849B, a Novel and Selective Candidate for the Treatment of Polycythemia Vera

Potential Mechanisms of JAK2V617F Somatic Mutation Contributing Distinct Phenotypes in Myeloproliferative Neoplasms," Myeloproliferative Neoplasms. Int. J. Mol. Sci, vol. 2022, p. 1013, 2022,  doi: 10.3390/ijms.Grunwald, M. R.; Stein, B. L.; Boccia, R. V.; Oh, S. T.; Paranagama, D.; Parasuraman,

More news about: Vanda Pharmaceuticals Inc.

ITF Therapeutics Announces Publication of Positive Long-Term Data Reinforcing Givinostat Efficacy and Safety as a Treatment for Duchenne Muscular Dystrophy

Aug 25, 2025, 08:00 ET ITF Therapeutics Announces Publication of Positive Long-Term Data Reinforcing Givinostat Efficacy and Safety as a Treatment for Duchenne Muscular Dystrophy

Sandonà M, Cavioli G, Renzini A, et al. Histone Deacetylases: Molecular Mechanisms and Therapeutic Implications for Muscular Dystrophies. Int J Mol Sci. 2023;24(5):4306.

More news about: ITF Therapeutics LLC

Aug 25, 2025, 03:31 ET Leqembi® (lecanemab) launched in the EU today

doi:10.1038/s41467-021-23507-z. vi Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706. vii Froelich L., et al. Lecanemab for treatment

More news about: BioArctic

Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.